Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Washington University School of Medicine
Washington University School of Medicine
Mayo Clinic
Stanford University
Ohio State University Comprehensive Cancer Center
Case Comprehensive Cancer Center
Mayo Clinic
Virginia Commonwealth University
Rutgers, The State University of New Jersey
St. Petersburg State Pavlov Medical University
British Columbia Cancer Agency
University of Arkansas
Karolinska Institutet
University of California, San Diego
University of Reading
McGill University Health Centre/Research Institute of the McGill University Health Centre